Jay Brad­ner’s NI­BR ex­it sets off a suc­ces­sion plan at Mer­ck; Dyne and Mor­phoSys fill ma­jor R&D roles

→ In the Big Phar­ma world, com­pa­nies like J&J and Mer­ck have ex­pe­ri­enced a pro­nounced sea change in lead­er­ship over a two-year pe­ri­od, and you can be­gin to say the same at No­var­tis, which dis­missed head of de­vel­op­ment John Tsai and head of on­col­o­gy Su­sanne Schaf­fert as part of CEO Vas Narasimhan’s wide-rang­ing re­struc­tur­ing plan. The next shoe to drop is Jay Brad­ner, the pres­i­dent of the No­var­tis In­sti­tutes for Bio­Med­ical Re­search, who is leav­ing his post on Hal­loween and pass­ing the ba­ton to Fiona Mar­shall, Mer­ck’s SVP and glob­al head of dis­cov­ery sci­ences, pre­clin­i­cal de­vel­op­ment and trans­la­tion­al med­i­cine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.